Enlivex Therapeutics is set to conduct a reverse merger with publicly traded Bioblast Pharma, which will be renamed to Enlivex following the transaction.

Enilvex Therapeutics, an Israel-based immunotherapy developer backed by medical provider Hadassah University Hospital, is set to undertake a reverse merger of biotechnology firm Bioblast Pharma. Upon closure of the transaction, Bioblast will rename to Enilvex Therapeutics and its ticker symbol on Nasdaq will be adapted from the current ORPN. The deal is expected to close…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.